NEWS 2021 | Appili Therapeutics

December 23, 2021

Appili Therapeutics – Press Release Correction

December 22, 2021

Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners

November 19, 2021

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

November 12, 2021

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer

November 12, 2021

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™

October 14, 2021

Appili Therapeutics Announces Closing of Public Offering of $7,000,220

October 7, 2021

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

October 6, 2021

Appili Therapeutics Announces Overnight Marketed Equity Offering

September 29, 2021

Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction

September 23, 2021

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19

September 20, 2021

Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients

September 17, 2021

Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub-Study for Mild-to-Moderate COVID-19 Patients

September 8, 2021

Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders

August 18, 2021

Appili Therapeutics Announces Closing of $3.5 Million Funding Agreement

August 13, 2021

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022

August 9, 2021

Appili Therapeutics Secures $3.5 Million in Funding

June 24, 2021

Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results Provides Update on Strategy for Fiscal 2022

June 17, 2021

Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil

May 17, 2021

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients

April 19, 2021

Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021